



29 December 2020

**OMEGA DIAGNOSTICS GROUP PLC**  
**("Omega" or the "Company" or the "Group")**

**Update re AbC-19™ Rapid Test**

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today's update from Abingdon Health plc (AIM: ABDX) regarding the AbC-19™ Rapid Test and welcomes confirmation that they continue to work constructively with the Medicines and Healthcare products Regulatory Agency (MHRA) to try to enable approval for home use and self-test of the AbC-19™ Rapid Test in the UK.

Abingdon have also confirmed that whilst the DHSC continues to have first refusal for supplies of the AbC-19™ Rapid Test through a Supply of Goods Contract that extends to 14 February 2021, the UK-RTC is liaising with customers and regulatory authorities across a total of 27 international territories, to allow future use of the product outside of the UK.

**Colin King, CEO of Omega Diagnostics, said:** *"We welcome the update from Abingdon Health this morning and we look forward to being able to update investors on this approval process for self-test use in due course. We remain confident that the AbC-19™ Rapid Test has a potential global application and we are delighted that the UK-RTC maintains constructive dialogue with interested customers and regulatory authorities across the world."*

**Contacts:**

**Omega Diagnostics Group PLC**

Bill Rhodes, Interim Non-Executive Chairman  
Colin King, Chief Executive  
Kieron Harbinson, Group Finance Director

Tel: 01259 763 030  
[www.omegadiagnostics.com](http://www.omegadiagnostics.com)

**finnCap Ltd**

Geoff Nash/Edward Whiley (Corporate Finance)  
Alice Lane (ECM)

Tel: 020 7220 0500

**Walbrook PR Limited**

Paul McManus

Tel: 020 7933 8780 or [omega@walbrookpr.com](mailto:omega@walbrookpr.com)  
Mob: 07980 541 893